| Trial ID: | L2205 |
| Source ID: | NCT02284425
|
| Associated Drug: |
Regn1193
|
| Title: |
Study of REGN1193 in Patients With Type 2 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: REGN1193|DRUG: Placebo
|
| Outcome Measures: |
Primary: Incidence and severity of treatment emergent adverse events (TEAEs), Day 1 through Day 57 | Secondary: Pharmacodynamic profile of REGN1193 as measured by plasma glucose over time, Day 1 through Day 57|Concentration of REGN1193 in serum over time, Day 1 through Day 57
|
| Sponsor/Collaborators: |
Sponsor: Regeneron Pharmaceuticals
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
72
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2014-10
|
| Completion Date: |
2015-12
|
| Results First Posted: |
|
| Last Update Posted: |
2016-05-12
|
| Locations: |
Miami, Florida, United States|Atlanta, Georgia, United States|Knoxville, Tennessee, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT02284425
|
